<DOC>
	<DOCNO>NCT01783717</DOCNO>
	<brief_summary>The purpose study examine effect exenatide body weight glycemic control subject obesity and/or diabetes mellitus due hypothalamic damage .</brief_summary>
	<brief_title>Effects Exenatide Obesity and/or Diabetes Mellitus Due Hypothalamic Damage</brief_title>
	<detailed_description>Patients hypothalamus lesion cause tumor hypothalamic region , craniopharyngioma germ cell tumor , inflammatory disease susceptible develop severe obesity diabetes mellitus . The occurrence hypothalamic obesity patient surgery without radiotherapy craniopharyngioma high 42-66 % , incidence type 2 diabetes mellitus twice much healthy control . Treatment obesity diabetes mellitus population crucial increase morbidity mortality . However , diet exercise intervention proven useless previous study . Safe effective medicine remain developed . Exenatide , GLP-1 receptor agonist , play antihyperglycemic role variety mechanism , enhance glucose-dependent insulin secretion , increase beta cell mass decrease glucagon secretion , possess potent ability induce satiety , slow gastric empty reduce food intake , result weight loss diabetic patient simple obesity . Previous animal study already show GLP-1 agonist exendin-4 lead reduction weight caloric intake rat model hypothalamic obesity . Therefore , investigator hypothesize exenatide treatment might lead weight loss hypothalamic obese patient improve glycemic control .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Be 18 55 year old ; 2 . Greater 6 month posttreatment ( include surgery , radiotherapy chemotherapy ) craniopharyngioma diseases hypothalamic region ; 3 . BMI≧28kg/m2 and/or diabetes mellitus ; 4 . Greater 3 month adequate replacement therapy hypothalamicpituitaryadrenal ( HPA ) axis hypothalamicpituitarythyroid ( HPT ) axis ; 5 . Sign inform consent document . 1 . Less 6 month post surgery radiotherapy chemotherapy craniopharyngioma diseases hypothalamic region ; 2 . Inadequate replacement HPA axis HPT axis undertake adjustment kind dose substitutive medicine ; 3 . Use weight loss drug initiation weight loss program within past 3 month ; 4 . Use GLP1 agonist analogues dipeptidyl peptidase IV ( DPPIV ) inhibitor within past 3 month ; 5 . History bariatric surgery ; 6 . Diagnosed simple obesity diabetes mellitus prior hypothalamic disorder , diagnose type 1 diabetes mellitus ; 7 . With endstagerenal disease history kidney transplant complicate acute/chronic kidney failure ( GFR≦30ml/min ) ; 8 . History inflammatory bowel disease gastroparesis gastric mortility problem ; 9 . History pancreatitis chronic cholecystitis ; 10 . History allergic reaction exenatide medication component ; 11 . Undertaking warfarin ; 12 . Pregnant lactating woman ; 13 . Are participate , participate drug clinical trial within past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>